{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T09:36:33Z","timestamp":1791279393085,"version":"4.1.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2007,12,27]],"date-time":"2007-12-27T00:00:00Z","timestamp":1198713600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Psychopharmacology"],"published-print":{"date-parts":[[2008,3]]},"DOI":"10.1007\/s00213-007-1020-8","type":"journal-article","created":{"date-parts":[[2007,12,26]],"date-time":"2007-12-26T13:48:01Z","timestamp":1198676881000},"page":"157-168","source":"Crossref","is-referenced-by-count":148,"title":["Effects of THC and lofexidine in a human laboratory model of marijuana withdrawal and relapse"],"prefix":"10.1007","volume":"197","author":[{"given":"Margaret","family":"Haney","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl L.","family":"Hart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne K.","family":"Vosburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra D.","family":"Comer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie Collins","family":"Reed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard W.","family":"Foltin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2007,12,27]]},"reference":[{"key":"1020_CR1","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1111\/j.1469-8986.1995.tb03410.x","volume":"32","author":"O Ajilore","year":"1995","unstructured":"Ajilore O, Stickgold R, Rittenhouse CD, Hobson JA (1995) Nightcap: laboratory and home-based evaluation of a portable sleep monitor. Psychophysiology 32:92\u201398","journal-title":"Psychophysiology"},{"key":"1020_CR2","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0006-8993(02)04169-0","volume":"966","author":"K Anggadiredja","year":"2003","unstructured":"Anggadiredja K, Yamaguchi T, Tanaka H, Shoyama Y, Watanabe S, Yamamoto T (2003) Prostaglandin E2 attenuates SR141716A-precipitated withdrawal in tetrahydrocannabinol-dependent mice. Brain Res 966:47\u201353","journal-title":"Brain Res"},{"key":"1020_CR3","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1037\/1064-1297.2.3.244","volume":"2","author":"JC Anthony","year":"1994","unstructured":"Anthony JC, Warner LA, Kessler RC (1994) Comparative epidemiology of dependence on tobacco, alcohol, controlled substances and inhalants: basic findings from the National Comorbidity Survey. Exp Clin Psychopharmacol 2:244\u2013268","journal-title":"Exp Clin Psychopharmacol"},{"key":"1020_CR4","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1111\/j.1460-9568.2004.03714.x","volume":"20","author":"GN Balerio","year":"2004","unstructured":"Balerio GN, Aso E, Berrendero F, Murtra P, Maldonado R (2004) Delta9-tetrahydrocannabinol decreases somatic and motivational manifestations of nicotine withdrawal in mice. Eur J Neurosci 20:2737\u20132748","journal-title":"Eur J Neurosci"},{"key":"1020_CR5","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S0376-8716(96)01289-6","volume":"43","author":"J Bearn","year":"1996","unstructured":"Bearn J, Gossop M, Strang J (1996) Randomized double-blind comparison of lofexidine and methadone in the in-patient treatment of opiate withdrawal. Drug Alcohol Depend 43:87\u201391","journal-title":"Drug Alcohol Depend"},{"key":"1020_CR6","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/S0376-8716(98)00030-1","volume":"50","author":"J Bearn","year":"1998","unstructured":"Bearn J, Gossop M, Strang J (1998) Accelerated lofexidine treatment regimen compared with conventional lofexidine and methadone treatment for inpatient opiate detoxification. Drug Alcohol Depend 50:227\u2013232","journal-title":"Drug Alcohol Depend"},{"key":"1020_CR7","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1080\/1355621031000069882","volume":"8","author":"T Beswick","year":"2003","unstructured":"Beswick T, Best D, Rees S, Bearn J, Gossop M, Strang J (2003) Major disruptions of sleep during treatment of the opiate withdrawal syndrome: differences between methadone and lofexidine detoxification treatments. Addict Biol 8:49\u201357","journal-title":"Addict Biol"},{"key":"1020_CR8","first-page":"S19","volume":"66","author":"S Boyd","year":"2002","unstructured":"Boyd S, Gorelick D, Huestis M, Heishman S, Dermand JC, Nides MA et al (2002) Prevalence and persistence of withdrawal symptoms reported by a non-treatment sample of marijuana smokers. Drug Alcohol Depend 66:S19","journal-title":"Drug Alcohol Depend"},{"key":"1020_CR9","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1111\/j.1530-0277.1998.tb03995.x","volume":"22","author":"KJ Brower","year":"1998","unstructured":"Brower KJ, Aldrich MS, Hall JM (1998) Polysomnographic and subjective sleep predictors of alcoholic relapse. Alcohol Clin Exp Res 22:1864\u20131871","journal-title":"Alcohol Clin Exp Res"},{"key":"1020_CR10","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1037\/1064-1297.6.4.419","volume":"6","author":"AJ Budney","year":"1998","unstructured":"Budney AJ, Radonovich KJ, Higgins ST, Wong CJ (1998) Adults seeking treatment for marijuana dependence: A comparison with cocaine-dependent treatment seekers. Exp Clin Psychopharmacology 6:419\u2013426","journal-title":"Exp Clin Psychopharmacology"},{"key":"1020_CR11","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1046\/j.1360-0443.1999.94913114.x","volume":"94","author":"AJ Budney","year":"1999","unstructured":"Budney AJ, Novy PL, Hughes JR (1999) Marijuana withdrawal among adults seeking treatment for marijuana dependence. Addiction 94:1311\u20131321","journal-title":"Addiction"},{"key":"1020_CR12","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1001\/archpsyc.58.10.917","volume":"58","author":"AJ Budney","year":"2001","unstructured":"Budney AJ, Hughes JR, Moore BA, Novy PL (2001) Marijuana abstinence effects in marijuana smokers maintained in their home environment. Arch Gen Psychiatry 58:917\u2013924","journal-title":"Arch Gen Psychiatry"},{"key":"1020_CR13","first-page":"S23","volume":"66","author":"AJ Budney","year":"2002","unstructured":"Budney AJ, Moore BA, Vandrey RA, Hughes JR (2002) Onset, magnitude, and duration of abstinence effects following heavy marijuana use. Drug Alcohol Depend 66:S23","journal-title":"Drug Alcohol Depend"},{"key":"1020_CR14","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1176\/appi.ajp.161.11.1967","volume":"11","author":"AJ Budney","year":"2004","unstructured":"Budney AJ, Hughes JR, Moore BA, Vandry R (2004) Review of the validity and significance of the cannabis withdrawal syndrome. Am J Psychiatry 11:1967\u20131977","journal-title":"Am J Psychiatry"},{"key":"1020_CR15","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.drugalcdep.2006.04.014","volume":"86","author":"AJ Budney","year":"2007","unstructured":"Budney AJ, Vandrey RG, Hughes JR, Moore BA, Bahrenburg B (2007) Oral delta-9 tetrahydrocannabinol suppresses cannabis withdrawal symptoms. Drug Alcohol Depend 86:22\u201329","journal-title":"Drug Alcohol Depend"},{"key":"1020_CR16","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/S0022-3565(24)36669-8","volume":"281","author":"AJ Carter","year":"1997","unstructured":"Carter AJ (1997) Hippocampal noradrenaline release in awake, freely moving rats is regulated by alpha-2 adrenoceptors but not by adenosine receptors. J Pharmacol Exp Ther 281:648\u2013654","journal-title":"J Pharmacol Exp Ther"},{"key":"1020_CR17","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1001\/jama.291.17.2114","volume":"291","author":"WM Compton","year":"2004","unstructured":"Compton WM, Grant BF, Colliver JD, Glantz MD, Stinson FS (2004) Prevalence of marijuana use disorders in the United States: 1991\u20131992 and 2001\u20132002. JAMA 291:2114\u20132121","journal-title":"JAMA"},{"key":"1020_CR18","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0740-5472(01)00179-9","volume":"21","author":"J Copeland","year":"2001","unstructured":"Copeland J, Swift W, Roffman R, Stephens R (2001) A randomized controlled trial of brief cognitive-behavioral interventions for cannabis use disorder. J Subst Abuse Treatment 21:55\u201364","journal-title":"J Subst Abuse Treatment"},{"key":"1020_CR19","doi-asserted-by":"crossref","first-page":"17","DOI":"10.2165\/00003495-200059010-00003","volume":"59","author":"LS Covey","year":"2000","unstructured":"Covey LS, Sullivan MA, Johnston JA, Glassman AH, Robinson MD, Adams DP (2000) Advances in non-nicotine pharmacotherapy for smoking cessation. Drugs 59:17\u201331","journal-title":"Drugs"},{"key":"1020_CR20","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.1001\/jama.1988.03410200081030","volume":"260","author":"VP Dole","year":"1988","unstructured":"Dole VP (1988) Implications of methadone maintenance on theories of narcotic addiction. JAMA 260:3025\u20133029","journal-title":"JAMA"},{"key":"1020_CR21","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.drugalcdep.2006.11.019","volume":"89","author":"EC Donny","year":"2007","unstructured":"Donny EC, Dierker LC (2007) The absence of DSM-IV nicotine dependence in moderate-to-heavy daily smokers. Drug Alcohol Depend 89:93\u201396","journal-title":"Drug Alcohol Depend"},{"key":"1020_CR22","first-page":"176","volume":"6","author":"SM Evans","year":"1995","unstructured":"Evans SM, Foltin RW, Levin FR, Fischman MW (1995) Behavioral and subjective effects of DN-2327 (pazinaclone) and alprazolam in normal volunteers. Behav Pharmcol 6:176\u2013186","journal-title":"Behav Pharmcol"},{"key":"1020_CR23","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/0091-3057(87)90506-5","volume":"28","author":"RW Foltin","year":"1987","unstructured":"Foltin RW, Fischman MW, Pedroso JJ, Pearlson GD (1987) Marijuana and cocaine interactions in humans: cardiovascular consequences. Pharmacol Biochem Behavior 28:459\u2013464","journal-title":"Pharmacol Biochem Behavior"},{"key":"1020_CR24","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/0031-9384(95)02098-5","volume":"59","author":"RW Foltin","year":"1996","unstructured":"Foltin RW, Haney M, Comer SD, Fischman MW (1996) Effects of fenfluramine in food intake, mood, and performance of humans living in a residential laboratory. Physiol Behav 59:295\u2013305","journal-title":"Physiol Behav"},{"key":"1020_CR25","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s002130050848","volume":"141","author":"M Haney","year":"1999","unstructured":"Haney M, Ward AS, Comer SD, Foltin RW, Fischman MW (1999a) Abstinence symptoms following oral THC administration to humans. Psychopharmacology 141:385\u2013394","journal-title":"Psychopharmacology"},{"key":"1020_CR26","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s002130050849","volume":"141","author":"M Haney","year":"1999","unstructured":"Haney M, Ward AS, Comer SD, Foltin RW, Fischman MW (1999b) Abstinence symptoms following smoked marijuana in humans. Psychopharmacology 141:395\u2013404","journal-title":"Psychopharmacology"},{"key":"1020_CR27","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s002130000657","volume":"155","author":"M Haney","year":"2001","unstructured":"Haney M, Ward AS, Comer SD, Hart CL, Foltin RW, Fischman MW (2001) Bupropion SR worsens mood during marijuana withdrawal in humans. Psychopharmacology 155:171\u2013179","journal-title":"Psychopharmacology"},{"key":"1020_CR28","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s00213-002-1210-3","volume":"165","author":"M Haney","year":"2003","unstructured":"Haney M, Hart CL, Ward AS, Foltin RW (2003) Nefazodone decreases anxiety during marijuana withdrawal in humans. Psychopharmacology 165:157\u2013165","journal-title":"Psychopharmacology"},{"key":"1020_CR29","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/sj.npp.1300310","volume":"29","author":"M Haney","year":"2004","unstructured":"Haney M, Hart CL, Vosburg SK, Nasser J, Bennett A, Zubaran C et al (2004) Marijuana withdrawal in humans: effects of oral THC or Divalproex. Neuropsychopharmacology 29:158\u2013170","journal-title":"Neuropsychopharmacology"},{"key":"1020_CR30","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.drugalcdep.2005.03.027","volume":"80","author":"CL Hart","year":"2005","unstructured":"Hart CL (2005) Increasing treatment options for cannabis dependence: a review of potential pharmacotherapies. Drug Alcohol Depend 80:147\u2013159","journal-title":"Drug Alcohol Depend"},{"key":"1020_CR31","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/s00213-002-1231-y","volume":"164","author":"C Hart","year":"2002","unstructured":"Hart C, Ward AS, Haney M, Comer SD, Foltin RW, Fischman MW (2002) Comparison of smoked marijuana and oral d9-tetrahydrocannabinol in humans. Psychopharmacology 164:407\u2013415","journal-title":"Psychopharmacology"},{"key":"1020_CR32","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1006\/smns.1997.0115","volume":"9","author":"BH Herman","year":"1997","unstructured":"Herman BH, O\u2019Brien CP (1997) Clinical medications development for opiate addiction: focus on nonopioids and opioid antagonists for the amelioration of opiate withdrawal symptoms and relapse prevention. Semin Neurosci 9:158\u2013172","journal-title":"Semin Neurosci"},{"key":"1020_CR33","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0376-8716(96)01316-6","volume":"44","author":"A Kahn","year":"1997","unstructured":"Kahn A, Mumford JP, Rogers GA, Beckford H (1997) Double-blind study of lofexidine and clonidine in the detoxification of opiate addicts in hospital. Drug Alcohol Depend 44:57\u201361","journal-title":"Drug Alcohol Depend"},{"key":"1020_CR34","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1037\/1064-1297.8.4.483","volume":"8","author":"EM Kouri","year":"2000","unstructured":"Kouri EM, Pope HG Jr (2000) Abstinence symptoms during withdrawal from chronic marijuana use. Exp Clin Psychopharm 8:483\u2013492","journal-title":"Exp Clin Psychopharm"},{"key":"1020_CR35","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S0740-5472(99)00104-X","volume":"19","author":"E Lang","year":"2000","unstructured":"Lang E, Engelander M, Brooke T (2000) Report of an integrated brief intervention with self-defined problem cannabis users. J Subst Abuse Treat 19:111\u2013116","journal-title":"J Subst Abuse Treat"},{"key":"1020_CR36","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1080\/10550490490265280","volume":"13","author":"FR Levin","year":"2004","unstructured":"Levin FR, McDowell D, Evans SM, Nunes E, Akerele E, Donovan S et al (2004) Pharmacotherapy for marijuana dependence: a double-blind, placebo-controlled pilot study of divalproex sodium. Am J Addict 13:21\u201332","journal-title":"Am J Addict"},{"key":"1020_CR37","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0091-3057(01)00514-7","volume":"69","author":"AH Lichtman","year":"2001","unstructured":"Lichtman AH, Fisher J, Martin BR (2001) Precipitated cannabinoid withdrawal is reversed by Delta(9)-tetrahydrocannabinol or clonidine. Pharmacol Biochem Behav 69:181\u2013188","journal-title":"Pharmacol Biochem Behav"},{"key":"1020_CR38","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0376-8716(97)00116-6","volume":"48","author":"SK Lin","year":"1997","unstructured":"Lin SK, Strang J, Su LW, Tsai CJ, Hu WH (1997) Double-blind randomised controlled trial of lofexidine versus clonidine in the treatment of heroin withdrawal. Drug Alcohol Depend 48:127\u2013133","journal-title":"Drug Alcohol Depend"},{"key":"1020_CR39","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S0740-5472(03)00083-7","volume":"25","author":"BA Moore","year":"2003","unstructured":"Moore BA, Budney AJ (2003) Relapse in outpatient treatment for marijuana dependence. J Subst Abuse Treat 25:85\u201389","journal-title":"J Subst Abuse Treat"},{"key":"1020_CR40","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1080\/02791072.1988.10524382","volume":"20","author":"RA Roffman","year":"1988","unstructured":"Roffman RA, Stephens RS, Simpson EE, Whitaker DL (1988) Treatment of marijuana dependence: preliminary results. J Psychoactive Drugs 20:129\u2013137","journal-title":"J Psychoactive Drugs"},{"key":"1020_CR41","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s00213-002-1224-x","volume":"168","author":"Y Shaham","year":"2003","unstructured":"Shaham Y, Shalev U, Lu L, De Wit H, Stewart J (2003) The reinstatement model of drug relapse: history, methodology and major findings. Psychopharmacology 168:3\u201320","journal-title":"Psychopharmacology"},{"key":"1020_CR42","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s002130050022","volume":"148","author":"S Shiffman","year":"2000","unstructured":"Shiffman S, Johnston JA, Khayrallah M, Elash CA, Gwaltney CJ, Paty JA et al (2000) The effect of bupropion on nicotine craving and withdrawal. Psychopharmacology 148:33\u201340","journal-title":"Psychopharmacology"},{"key":"1020_CR43","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1007\/s00213-006-0640-8","volume":"190","author":"R Sinha","year":"2007","unstructured":"Sinha R, Kimmerling A, Doebrick C, Kosten TR (2007) Effects of lofexidine on stress-induced and cue-induced opioid craving and opioid abstinence rates: preliminary findings. Psychopharmacology 190:569\u2013574","journal-title":"Psychopharmacology"},{"key":"1020_CR44","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1037\/0022-006X.61.6.1100","volume":"61","author":"RS Stephens","year":"1993","unstructured":"Stephens RS, Roffman RA, Simpson EE (1993) Adult marijuana users seeking treatment. J Consult Clin Psychology 61:1100\u20131104","journal-title":"J Consult Clin Psychology"},{"key":"1020_CR45","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1037\/0022-006X.62.1.92","volume":"62","author":"RS Stephens","year":"1994","unstructured":"Stephens RS, Roffman RA, Simpson EE (1994) Treating adult marijuana dependence: a test of the relapse prevention model. J Consult Clin Psychology 62:92\u201399","journal-title":"J Consult Clin Psychology"},{"key":"1020_CR46","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1037\/0022-006X.68.5.898","volume":"68","author":"RS Stephens","year":"2000","unstructured":"Stephens RS, Roffman RA, Curtin L (2000) Extended versus brief treatment for marijuana use. J Consult Clin Psychology 68:898\u2013908","journal-title":"J Consult Clin Psychology"},{"key":"1020_CR47","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1080\/105504999305749","volume":"8","author":"J Strang","year":"1999","unstructured":"Strang J, Bearn J, Gossop M (1999) Lofexidine for opiate detoxification: review of recent randomized and open controlled trials. Am J Addict 8:337\u2013348","journal-title":"Am J Addict"},{"key":"1020_CR48","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1212\/WNL.46.5.1470","volume":"46","author":"The Consensus Committee of the American Autonomic Society and the American Academy of Neurology","year":"1996","unstructured":"The Consensus Committee of the American Autonomic Society and the American Academy of Neurology (1996) Consensus statement on the definition of orthostatic hypotension, pure autonomic failure, and multiple system atrophy. Neurology 46:1470","journal-title":"Neurology"},{"key":"1020_CR49","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/0165-1781(80)90005-0","volume":"2","author":"TW Uhde","year":"1980","unstructured":"Uhde TW, Redmond DE Jr, Kleber HD (1980) Clonidine suppresses the opioid abstinence syndrome without clonidine-withdrawal symptoms: a blind inpatient study. Psychiatry Res 2:37\u201347","journal-title":"Psychiatry Res"},{"key":"1020_CR50","first-page":"227","volume":"180","author":"E Yu","year":"2000","unstructured":"Yu E, Herman BH, Miotto K, Montgomery A, Fudala PJ, Fisher C et al (2000) In-patient safety evaluation of lofexidine, an alpha-2 adrenergic agonist, as a medication for opiate withdrawal. NIDA Research Monograph 180:227","journal-title":"NIDA Research Monograph"}],"container-title":["Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-007-1020-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00213-007-1020-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-007-1020-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T20:22:50Z","timestamp":1737750170000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00213-007-1020-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,12,27]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2008,3]]}},"alternative-id":["1020"],"URL":"https:\/\/doi.org\/10.1007\/s00213-007-1020-8","relation":{},"ISSN":["0033-3158","1432-2072"],"issn-type":[{"value":"0033-3158","type":"print"},{"value":"1432-2072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,12,27]]}}}